Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
ESMO 2023 – low-dose volrustomig hints at a therapeutic window
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
